An analysis of AccessHope case reviews found that experts recommended changes in more than 80% of cases. About half were implemented, saving a median of $18,636 per case.
|Articles|August 1, 2012
Employers Move to Adapt to Health Law
Advertisement
Two major provisions of the health-overhaul law take effect Wednesday, testing employers' ability to adapt to changes the measure mandates.
The law requires employers to distribute millions of dollars in insurance-company refunds to workers whose plans spent a high percentage of their premium dollars on administrative expenses instead of medical care.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
Advertisement
Advertisement
Trending on AJMC
1
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
2
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
3
Tegoprubart Eases Symptom Burden vs Tacrolimus After Kidney Transplant
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5